Modulating GBP5—suppressing it in breast cancer with siRNA or enhancing it in lung cancer with agonists—could optimize immunotherapy outcomes, leveraging its immune checkpoint influence to boost PD-L1 blockade efficacy, monitorable via immune cell infiltration assays, T cell function tests, or tumor response metrics. This evidence concerns the gene GBP5 and breast cancer.